Clinical Handbook of Psychotropic Drugs

Ric M. Procyshyn; BSc (Pharm), MSc, PharmD, PhD; Department ofPsychiatry, University of British Columbia, Vancouver, BC, Canada;British Columbia Mental Health & Addictions Research Institute,Vancouver, BC, Canada.Kalyna Z. Bezchlibnyk-Butler; BScPhm, FCSHP; Toronto, ON, Canada.J. Joel Jeffries; MB, FRCPC, DFCPA; Centre for Addiction and MentalHealth and Department of Psychiatry, University of Toronto,Toronto, ON, Canada.

AntidepressantsSelective Serotonin Reuptake Inhibitors (SSRI) * Norepinephrine Dopamine Reuptake Inhibitor (NDRI) * Serotonin Norepinephrine Re-uptake Inhibitor (SNRI) * Serotonin-2 Antagonists / Reuptake Inhibitors (SARI) * Serotonin-1A Agonist/Serotonin Reuptake Inhibitor * Serotonin Modulator and Stimulator (SMS) * Noradrenergic / Specific Seroto-nergic Antidepressants (NaSSA) * Nonselective Cyclic Antidepres-sants * Monoamine Oxidase Inhibitors * Reversible Inhibitor of MAO-A (RIMA) * Irreversible Monoamine Oxidase (A&B) Inhibitors (MAOIs) * Ir-reversible MAO-B Inhibitor * Effects of Antidepressants on Neurotrans-mitters / Receptors * Pharmacological Effects of Antidepressants on Neurotransmitters / Receptors * Frequency of Adverse Reactions to Antidepressants at Therapeutic Doses * Antidepressant Doses and Pharmacokinetics * Switching Antidepressants * Antidepressant Aug-mentation StrategiesElectroconvulsive Therapy (ECT)Bright Light Therapy (BLT)RepetitiveTranscranialMagneticStimulation (rTMS)Antipsychotics"Second-Generation" Antipsychotics / SGAs * "Third-Generation" Anti-psychotic / TGA * "First-Generation" Antipsychotics / FGAs * Effects of Antipsychotics on Neurotransmitters / Receptors * Pharmacological Ef-fects of Antipsychotics on Neurotransmitters / Receptor Subtypes * Rel-ative Tolerability Profiles of Antipsychotics * Frequency of Adverse Reactions to Antipsychotics at Therapeutic Doses * Antipsychotic Doses and Pharmacokinetics (Oral and Short-Acting Injections) * Comparison of Long-Acting IM Antipsychotics * Switching Antipsychotics * Antipsy-chotic Augmentation StrategiesAntipsychotic-Induced Extrapyramidal Side Effects and Their ManagementExtrapyramidal Adverse Effects of Antipsychotics * Treatment Options for Extrapyramidal Side Effects * Effects on Extrapyramidal Symp-toms * Comparison of Agents for Treating Acute Extrapyramidal Side Effects * Doses and Pharmacokinetics of Agents for Treating Acute Extrapyramidal Side EffectsAnxiolytic (Antianxiety) AgentsBenzodiazepines * Comparison of the Benzodiazepines * Buspirone Hypnotics/SedativesL-Tryptophan * Comparison of Hypnotics / SedativesMood StabilizersLithium * Anticonvulsants * Comparison of Anticonvulsants * Frequency of Adverse Reactions to Mood Stabilizers at Therapeutic DosesDrugs for ADHDPsychostimulants * Atomoxetine * Comparison of Drugs for ADHD * alpha2Agonists * Augmentation Strategies in ADHDDrugs for Treatment of DementiaCholinesterase Inhibitors * Memantine * Comparison of Drugs for Treatment of DementiaSex-Drive DepressantsComparison of Sex-Drive DepressantsDrugs of AbuseAlcohol * Stimulants * Hallucinogens * Opioids * Inhalants / Aerosols* Gamma-hydroxybutyrate (GHB) / Sodium Oxybate * Flunitrazepam (Rohypnol) * Nicotine / TobaccoTreatment of Substance Use DisordersAcamprosate * Disulfiram * Naltrexone * Buprenorphine * Metha-done * Pharmacotherapy for Nicotine / Tobacco Use DependenceUnapproved Treatments of Psychiatric Disorders5-HT3 Antagonists * Adrenergic Agents * Anti-Inflammatory Agents * Do-paminergic Agents * GABA Agents / Anticonvulsants * Hormones * NMDA Agents * MiscellaneousNaturalHealthProductsPharmacogenomic Information for Common Psychotropic DrugsGlossaryResources for Information on Drug Use in Pregnancy and Effects on Breast MilkNeuroscience-Based NomenclaturePatientInformationSheetsIndexofDrugs